News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Regeneron Pharmaceuticals, Inc. (REGN) Announces September 2012 Investor Conference Presentations


8/29/2012 11:01:29 AM

TARRYTOWN, N.Y., Aug. 29, 2012 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) will webcast management presentations at the following investor conferences:

  • Robert W. Baird Healthcare Conference at 1:20 p.m. Eastern Time on Wednesday, September 5, 2012
  • Morgan Stanley Global Healthcare Conference at 3:55 p.m. Eastern Time on Tuesday, September 11, 2012
  • UBS Global Life Sciences Conference at 7:30 a.m. Eastern Time on Thursday, September 20, 2012

The sessions may be accessed through the Company's web site, www.regeneron.com, on the Events and Presentations page. Archived versions of the presentations will be available for thirty days after the live webcasts.

Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use. Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.

Contact Information:


Manisha Narasimhan, Ph.D.

Peter Dworkin

Investor Relations

Corporate Communications

914-847-5126

914.847.7640

manisha.narasimhan@regeneron.com

peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES